1. Home
  2. CHGG vs DMAC Comparison

CHGG vs DMAC Comparison

Compare CHGG & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chegg Inc.

CHGG

Chegg Inc.

HOLD

Current Price

$0.73

Market Cap

63.6M

Sector

Real Estate

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$6.55

Market Cap

428.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHGG
DMAC
Founded
2005
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.6M
428.6M
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
CHGG
DMAC
Price
$0.73
$6.55
Analyst Decision
Sell
Strong Buy
Analyst Count
2
4
Target Price
N/A
$15.50
AVG Volume (30 Days)
789.0K
207.2K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
88.15
N/A
EPS
N/A
N/A
Revenue
$376,908,000.00
$500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$3.26
52 Week High
$1.89
$10.42

Technical Indicators

Market Signals
Indicator
CHGG
DMAC
Relative Strength Index (RSI) 57.83 36.27
Support Level $0.53 $5.20
Resistance Level $0.83 $7.33
Average True Range (ATR) 0.06 0.47
MACD 0.02 -0.01
Stochastic Oscillator 74.91 27.74

Price Performance

Historical Comparison
CHGG
DMAC

About CHGG Chegg Inc.

Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Chegg Skilling; and Academic Services, which derives maximum revenue. Geographically, it derives in United States and International.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: